Amarin Corp Plcuk (AMRN) Other Accumulated Expenses (2010 - 2025)
Amarin Corp Plcuk (AMRN) reported Other Accumulated Expenses of $18.3 million for Q4 2025, up 4.52% year-over-year from $17.5 million in Q4 2024, and up 4.52% quarter-over-quarter from $17.5 million in Q4 2024.
Amarin Corp Plcuk (AMRN) Other Accumulated Expenses (2010 - 2025) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 16 years of Other Accumulated Expenses data on file, last reported at $18.3 million in Q4 2025.
- Other Accumulated Expenses for Q4 2025 came in at $18.3 million, up 4.52% year-over-year; the trailing twelve-month figure through Dec 2025 was $18.3 million (up 4.52% YoY), and the FY2025 annual result was $18.3 million, up 4.52% from the prior year.
- Other Accumulated Expenses grew to $18.3 million in Q4 2025 per AMRN's latest filing, from $17.5 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $45.6 million in Q4 2021 and troughed at $17.5 million in Q4 2024.
- A 5-year average of $28.0 million and a median of $23.0 million in 2023 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2021 and 2023: Other Accumulated Expenses surged 58.42% in 2021, then sank 35.41% in 2023.
- A 5-year view of Other Accumulated Expenses shows it stood at $45.6 million in 2021, then fell by 21.84% to $35.6 million in 2022, then slumped by 35.41% to $23.0 million in 2023, then decreased by 23.79% to $17.5 million in 2024, then advanced by 4.52% to $18.3 million in 2025.
- Business Quant data shows AMRN's Other Accumulated Expenses at $18.3 million in Q4 2025, $17.5 million in Q4 2024, and $23.0 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.34 Mn |
| Dec 31, 2024 | 17.55 Mn |
| Dec 31, 2023 | 23.02 Mn |
| Dec 31, 2022 | 35.64 Mn |
| Dec 31, 2021 | 45.60 Mn |
| Dec 31, 2020 | 28.79 Mn |
| Dec 31, 2019 | 16.59 Mn |
| Dec 31, 2018 | 7.71 Mn |
| Dec 31, 2017 | 5.16 Mn |
| Dec 31, 2016 | 5.80 Mn |
| Dec 31, 2015 | 4.28 Mn |
| Dec 31, 2014 | 2.25 Mn |
| Dec 31, 2013 | 3.34 Mn |
| Dec 31, 2012 | 3.15 Mn |
| Dec 31, 2011 | 1.78 Mn |
| Dec 31, 2010 | 572,000.00 |